WHO warns of contaminated India cough syrups
Saddam Mansuri, the father of two, shows bottles of Coldrif, linked to the deaths of several children and a Relife cough syrup, which is not linked to any deaths, but Indian authorities have asked people to avoid it, which he had been giving his one-year-
(Corrects Chhindwara to 'district', not 'city' in paragraph 4)
(Reuters) -The World Health Organization on Monday issued a health advisory warning about three contaminated cough syrups identified in India, urging authorities to report any detection of these medicines in their countries to the health agency.
The WHO said the affected medicines are specific batches of Coldrif from Sresan Pharmaceutical, Respifresh TR from Rednex Pharmaceuticals and ReLife from Shape Pharma.
The agency said the contaminated products pose significant risks and can cause severe, potentially life-threatening illness.
India's health authority, the Central Drugs Standard Control Organization, informed the WHO the syrups were reportedly consumed by children, all under the age of five, who recently died in the central state of Madhya Pradesh's Chhindwara district.
The cough medicine contained toxic diethylene glycol in quantities nearly 500 times the permissible limit.
CDSCO said none of the contaminated medicines have been exported from India and there is no evidence of illegal export.
The U.S. Food and Drug Administration confirmed on Friday that these toxic cough syrups had not been shipped to the United States.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid and Vijay Kishore)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bumble forecasts downbeat quarterly revenue as paying users drop
- Brazil central bank cuts rates by 25 bps at fourth straight meeting
- MercadoLibre's net profit beats estimates despite third straight decline
Create E-mail Alert Related Categories
ReutersRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share